SEE MORE: Clinton Delivers Poison Pill To Biotech ETFs

Clinton’s statement renewed fear of “more political risk around drug pricing concerns and potential changes in the future,” Michael Yee, an analyst with RBC Capital Markets, said in a note.

“This risk is not going to just go away, but it has been quieter and lower in the political agenda over the last six months and just happens to be something new that has come up after nothing much recently and after a big biotech rally and investors were taken by surprise,” Yee added.

For more information on the biotech sector, visit our biotechnology category.

iShares Nasdaq Biotechnology ETF